← Back to the Areas of Interest
Bristol Myers Squibb - Harnessing the potential of the immune system: Clinical insights from utilizing CTLA-4 within a dual I-O approach in aRCC
View the full invitation
Merck Pfizer Alliance - 2020: New decade, new treatment choices in GU cancer (Medical)
Ipsen - What does the changing treatment landscape for aRCC mean for patient care: An expert discussion
MSD - Multiple immunotherapeutic options: Clinical decision making in advanced renal cell carcinoma and urothelial carcinoma
F. Hoffmann-La Roche Ltd. - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Programme and Faculty are preliminary and subject to change.
© 2019 cSLIDE CTI MEETING TECHNOLOGY. All rights reserved.